About this Journal Submit a Manuscript Table of Contents
Parkinson’s Disease
Volume 2012 (2012), Article ID 321406, 8 pages
http://dx.doi.org/10.1155/2012/321406
Research Article

L-DOPA Uptake in Astrocytic Endfeet Enwrapping Blood Vessels in Rat Brain

1Department of Physiology, Universidad Central del Caribe, Bayamón, PR 00956, USA
2Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

Received 14 March 2012; Accepted 13 June 2012

Academic Editor: Heinz Reichmann

Copyright © 2012 M. Y. Inyushin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Simard, G. Arcuino, T. Takano, Q. S. Liu, and M. Nedergaard, “Signaling at the gliovascular interface,” The Journal of Neuroscience, vol. 23, no. 27, pp. 9254–9262, 2003. View at Scopus
  2. R. L. Heimark, “Cell-cell adhesion of molecules the blood-brain barrier,” in The Blood-brain Barrier: Cellular and Molecular Biology, W. M. Pardridge, Ed., pp. 88–106, Lippincott-Raven, New York, NY, USA, 1993.
  3. M. W. Brightman and T. S. Reese, “Junctions between intimately apposed cell membranes in the vertebrate brain,” Journal of Cell Biology, vol. 40, no. 3, pp. 648–677, 1969. View at Scopus
  4. S. Morgello, R. R. Uson, E. J. Schwartz, and R. S. Haber, “The human blood-brain barrier glucose transporter (GLUT1) is a glucose transporter of gray matter astrocytes,” GLIA, vol. 14, no. 1, pp. 43–54, 1995. View at Scopus
  5. T. Kageyama, M. Nakamura, A. Matsuo et al., “The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier,” Brain Research, vol. 879, no. 1-2, pp. 115–121, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Matsuo, S. Tsukada, T. Nakata et al., “Expression of a system L neutral amino acid transporter at the blood-brain barrier,” Neuroreport, vol. 11, no. 16, pp. 3507–3511, 2000. View at Scopus
  7. H. Uchino, Y. Kanai, D. K. Kim et al., “Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition,” Molecular Pharmacology, vol. 61, no. 4, pp. 729–737, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Ohtsuki, H. Yamaguchi, Y. S. Kang, S. Hori, and T. Terasaki, “Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease,” Biological and Pharmaceutical Bulletin, vol. 33, no. 7, pp. 1250–1252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Kanai, H. Segawa, K. Miyamoto, H. Uchino, E. Takeda, and H. Endou, “Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98),” Molecular Pharmacology, vol. 61, no. 4, pp. 729–737, 2002.
  10. M. J. Tsai and E. N. Y. Lee, “Characterization of L-DOPA transport in cultured rat and mouse astrocytes,” Journal of Neuroscience Research, vol. 43, pp. 490–495, 1996.
  11. D. K. Kim, I. J. Kim, S. Hwang et al., “System L-amino acid transporters are differently expressed in rat astrocyte and C6 glioma cells,” Neuroscience Research, vol. 50, no. 4, pp. 437–446, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Inazu, H. Takeda, and T. Matsumiya, “Functional expression of the norepinephrine transporter in cultured rat astrocytes,” Journal of Neurochemistry, vol. 84, no. 1, pp. 136–144, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Inazu, H. Takeda, and T. Matsumiya, “Molecular and functional characterization of an Na+-independent choline transporter in rat astrocytes,” Journal of Neurochemistry, vol. 94, no. 5, pp. 1427–1437, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. P. C. Pinto-do-Ó and P. Soares-da-Silva, “Studies on the pharmacology of the inward transport of L-DOPA in rat renal tubules,” British Journal of Pharmacology, vol. 118, no. 3, pp. 741–747, 1996. View at Scopus
  15. M. Becker, L. Visser, R. van Schaik, A. Hofman, A. Uitterlinden, and B. Stricker, “OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users,” Neurogenetics, vol. 12, no. 1, pp. 79–82, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Bertler, B. Falck, C. Owman, and E. Rosengrenn, “The localization of monoaminergic blood-brain barrier mechanisms,” Pharmacological Reviews, vol. 18, no. 1, part 1, pp. 369–385, 1966. View at Scopus
  17. L. A. Wade and R. Katzman, “Rat brain regional uptake and decarboxylation of l DOPA following carotid injection,” American Journal of Physiology, vol. 228, no. 2, pp. 352–359, 1975. View at Scopus
  18. J. E. Hardebo, B. Falck, and C. Owman, “A comparative study on the uptake and subsequent decarboxylation of monoamine precursors in cerebral microvessels,” Acta Physiologica Scandinavica, vol. 107, no. 2, pp. 161–167, 1979. View at Scopus
  19. J. C. De la Torre, “An improved approach to histofluorescence using the SPG method for tissue monoamines,” Journal of Neuroscience Methods, vol. 3, no. 1, pp. 1–5, 1980. View at Publisher · View at Google Scholar · View at Scopus
  20. T. A. Ryder, M. L. MacKenzie, J. Pryse-Davies, V. Glover, R. Lewinsohn, and M. Sandler, “A coupled peroxidatic oxidation technique for the histochemical localization of monoamine oxidase A and B and benzylamine oxidase,” Histochemistry, vol. 62, no. 1, pp. 93–100, 1979. View at Scopus
  21. J. Willoughby, V. Glover, and M. Sandler, “Histochemical localisation of monoamine oxidase A and B in rat brain,” Journal of Neural Transmission, vol. 74, no. 1, pp. 29–42, 1988. View at Scopus
  22. M. Zhou and H. K. Kimelberg, “Freshly isolated astrocytes from rat hippocampus show two distinct current patterns and different [K+]o uptake capabilities,” Journal of Neurophysiology, vol. 84, no. 6, pp. 2746–2757, 2000. View at Scopus
  23. J. W. Schwartz, R. D. Blakely, and L. J. DeFelice, “Binding and transport in norepinephrine transporters: real-time, spatially resolved analysis in single cells using a fluorescent substrate,” The Journal of Biological Chemistry, vol. 278, no. 11, pp. 9768–9777, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Mehrens, S. Lelleck, I. Çetinkaya et al., “The affinity of the organic cation transporter rOCT1 is increased by protein kinase C-dependent phosphorylation,” Journal of the American Society of Nephrology, vol. 11, no. 7, pp. 1216–1224, 2000. View at Scopus
  25. I. Çetinkaya, G. Ciarimboli, G. Yalçinkaya et al., “Regulation of human organic cation transporter hOCT2 by PKA, PI3K, and calmodulin-dependent kinases,” American Journal of Physiology, vol. 284, no. 2, pp. F293–F302, 2003. View at Scopus
  26. B. M. Schmitt and H. Koepsell, “Alkali cation binding and permeation in the rat organic cation transporter rOCT2,” The Journal of Biological Chemistry, vol. 280, no. 26, pp. 24481–24490, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Levitt, J. E. Pintar, and X. O. Breakefield, “Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 20, pp. 6385–6389, 1982. View at Scopus
  28. J. Saura, R. Kettler, M. Da Prada, and J. G. Richards, “Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain,” The Journal of Neuroscience, vol. 12, no. 5, pp. 1977–1999, 1992. View at Scopus
  29. A. Siddiqui, J. K. Mallajosyula, A. Rane, and J. K. Andersen, “Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression,” Neurobiology of Disease, vol. 40, no. 2, pp. 444–448, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Privat, M. Gimenez-Ribotta, and J.-C. Ridet, “Morphology of astrocytes,” in Neuroglia, B. R. Ransom and H. Kettenmann, Eds., pp. 3–22, Oxford University Press, New York, NY, USA, 1995.
  31. A. V. Juorio, X. M. Li, W. Walz, and I. A. Paterson, “Decarboxylation of L-Dopa by cultured mouse astrocytes,” Brain Research, vol. 626, no. 1-2, pp. 306–309, 1993. View at Publisher · View at Google Scholar · View at Scopus
  32. X. M. Li, A. V. Juorio, I. A. Paterson, W. Walz, M. Y. Zhu, and A. A. Boulton, “Gene expression of aromatic L-amino acid decarboxylase in cultured rat glial cells,” Journal of Neurochemistry, vol. 59, no. 3, pp. 1172–1175, 1992. View at Scopus
  33. T. Björklund, H. Hall, N. Breysse et al., “Optimization of continuous in vivo DOPA production and studies on ectopic da synthesis using rAAV5 vectors in Parkinsonian rats,” Journal of Neurochemistry, vol. 111, no. 2, pp. 355–367, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. B. R. Ransom, D. M. Kunis, I. Irwin, and J. W. Langston, “Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+,” Neuroscience Letters, vol. 75, no. 3, pp. 323–328, 1987. View at Scopus
  35. J. A. Javitch, R. J. D'Amato, S. M. Strittmatter, and S. H. Snyder, “Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 7, pp. 2173–2177, 1985. View at Scopus
  36. M. Cui, R. Aras, W. V. Christian et al., “The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 19, pp. 8043–8048, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Magrassi, D. Purves, and J. W. Lichtman, “Fluorescent probes that stain living nerve terminals,” The Journal of Neuroscience, vol. 7, no. 4, pp. 1207–1214, 1987. View at Scopus
  38. M. I. Papp, J. E. Kahn, and P. L. Lantos, “Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome),” Journal of the Neurological Sciences, vol. 94, no. 1–3, pp. 79–100, 1989. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Gilman, P. A. Low, N. Quinn et al., “Consensus statement on the diagnosis of multiple system atrophy,” Journal of the Neurological Sciences, vol. 163, no. 1, pp. 94–98, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Müller, “Motor complications, levodopa metabolism and progression of Parkinson's disease,” Expert Opinion on Drug Metabolism and Toxicology, vol. 7, no. 7, pp. 847–855, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Riederer, C. Konradi, V. Schay et al., “Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl,” Advances in Neurology, vol. 45, pp. 111–118, 1987. View at Scopus
  42. P. H. Yu and L. Hertz, “Differential expression of type A and type B monoamine oxidase of mouse astrocytes in primary cultures,” Journal of Neurochemistry, vol. 39, no. 5, pp. 1492–1495, 1982. View at Scopus
  43. M. B. Youdim, D. Edmondson, and K. F. Tipton, “The therapeutic potential of monoamine oxidase inhibitors,” Nature Reviews Neuroscience, vol. 7, no. 4, pp. 295–309, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. K. E. Ohlin, V. Francardo, H. S. Lindgren et al., “Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia,” in Brain, vol. 134, part 8, pp. 2339–2357, 2011.
  45. J. E. Westin, H. S. Lindgren, J. Gardi et al., “Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia,” The Journal of Neuroscience, vol. 26, no. 37, pp. 9448–9461, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Astradsson, B. G. Jenkins, J. K. Choi et al., “The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates-evidence from in vivo neuroimaging studies,” Neurobiology of Disease, vol. 35, no. 3, pp. 348–351, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Müller, K. Kolf, L. Ander, D. Woitalla, and S. Muhlack, “Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease,” Clinical Neuropharmacology, vol. 31, no. 3, pp. 134–140, 2008. View at Publisher · View at Google Scholar · View at Scopus